Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: Double-blind randomized proof of concept study

Medicine and Dentistry

• Patient 100%
• Mesalazine 83%
• Placebo 66%
• Adverse Event 50%
• Patient with Ulcerative Colitis 50%
• Inpatient 50%
• Therapeutic Procedure 33%
• Amaurosis 33%
• Measurement 16%
• Spontaneous Remission 16%
• Liver Enzyme 16%
• Bilirubin 16%
• Colitis 16%
• Colon Biopsy 16%
• Treatment Interruption 16%
• Platelet 16%
• Liver Function Test 16%
• Gene 16%
• Sigmoidoscopy 16%
• Granulomatous Colitis 16%
• Mechanism of Action 16%